CA3032473A1 - Topical rapamycin therapy - Google Patents

Topical rapamycin therapy Download PDF

Info

Publication number
CA3032473A1
CA3032473A1 CA3032473A CA3032473A CA3032473A1 CA 3032473 A1 CA3032473 A1 CA 3032473A1 CA 3032473 A CA3032473 A CA 3032473A CA 3032473 A CA3032473 A CA 3032473A CA 3032473 A1 CA3032473 A1 CA 3032473A1
Authority
CA
Canada
Prior art keywords
composition
rapamycin
weight
patient
glycol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3032473A
Other languages
English (en)
French (fr)
Inventor
Mary Kay Koenig
Hope NORTHRUP
Adelaide A. Hebert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The University of Texas System
Original Assignee
The University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University of Texas System filed Critical The University of Texas System
Publication of CA3032473A1 publication Critical patent/CA3032473A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3032473A 2016-08-10 2017-08-10 Topical rapamycin therapy Abandoned CA3032473A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662372940P 2016-08-10 2016-08-10
US62/372,940 2016-08-10
PCT/US2017/046320 WO2018031789A1 (en) 2016-08-10 2017-08-10 Topical rapamycin therapy

Publications (1)

Publication Number Publication Date
CA3032473A1 true CA3032473A1 (en) 2018-02-15

Family

ID=59684091

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3032473A Abandoned CA3032473A1 (en) 2016-08-10 2017-08-10 Topical rapamycin therapy

Country Status (11)

Country Link
US (1) US20190167649A1 (enExample)
EP (1) EP3496712A1 (enExample)
JP (1) JP2019527711A (enExample)
KR (1) KR20190039220A (enExample)
CN (1) CN109689053A (enExample)
AU (1) AU2017311491A1 (enExample)
BR (1) BR112019002689A2 (enExample)
CA (1) CA3032473A1 (enExample)
MX (1) MX2019001670A (enExample)
RU (1) RU2019106483A (enExample)
WO (1) WO2018031789A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018129364A1 (en) 2017-01-06 2018-07-12 Palvella Therapeutics Llc Anhydrous compositions of mtor inhibitors and methods of use
US12109199B2 (en) 2018-02-06 2024-10-08 Georgetown University Topical mTOR inhibitors for cutaneous proliferative and vascular conditions
EP3817743A4 (en) 2018-07-02 2022-07-06 Palvella Therapeutics, Inc. ANHYDROUS COMPOSITIONS OF MTOR INHIBITORS AND METHODS OF USE
WO2020047342A1 (en) * 2018-08-30 2020-03-05 Chemistryrx Sirolimus containing compositions
CN109431997B (zh) * 2018-12-20 2021-06-04 武汉科福新药有限责任公司 一种雷帕霉素局部注射制剂及其制备方法
AU2020226527A1 (en) 2019-02-20 2021-10-14 AI Therapeutics, Inc. Topical rapamycin formulations and their use in treating facial angiofibromas and other skin disorders
WO2020175131A1 (ja) * 2019-02-27 2020-09-03 国立大学法人大阪大学 脈管異常治療用外用剤
US20230056335A1 (en) 2020-01-24 2023-02-23 Nobelpharma Co., Ltd. Topical formulation containing rapamycin
AU2020277132B1 (en) * 2020-11-24 2021-11-04 Aft Pharmaceuticals Limited A Rapamycin Composition
AU2023203871B1 (en) * 2023-06-20 2024-07-25 Aft Pharmaceuticals Ltd A Rapamycin Method of Treatment and Composition

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606452D0 (en) 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
WO1998002441A2 (en) 1996-07-12 1998-01-22 Ariad Pharmaceuticals, Inc. Non immunosuppressive antifungal rapalogs
GB9723669D0 (en) 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components
EP1546369A4 (en) 2002-08-12 2007-01-17 Univ Michigan DIAGNOSIS AND TREATMENT OF DISEASES THROUGH DEFECTS IN THE TUBEROUS SKLEROSEPFAD
AU2006218918A1 (en) 2005-03-02 2006-09-08 Wyeth Purification of rapamycin
KR20140016439A (ko) 2006-02-02 2014-02-07 노파르티스 아게 결절성 경화증의 치료
US20120022095A1 (en) 2010-06-24 2012-01-26 Teng Joyce M C Topical rapamycin for treatment of facial angiofibromas in tuberous sclerosis
WO2012142145A1 (en) * 2011-04-12 2012-10-18 Dow Pharmaceutical Sciences Methods of treating skin conditions exhibiting telangiectasia
US10172789B2 (en) * 2013-01-24 2019-01-08 Palvella Therapeutics Llc Compositions for transdermal delivery of mTOR inhibitors
HUP1400075A2 (hu) * 2014-02-14 2015-08-28 Druggability Technologies Ip Holdco Jersey Ltd Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
WO2017053222A1 (en) * 2015-09-24 2017-03-30 Drexel University Novel compositions and methods for treating or preventing dermal disorders
CN105663027B (zh) * 2016-04-01 2018-12-18 中国人民解放军广州军区武汉总医院 西罗莫司外用制剂、其制备方法及用途

Also Published As

Publication number Publication date
WO2018031789A1 (en) 2018-02-15
BR112019002689A2 (pt) 2019-05-14
AU2017311491A1 (en) 2019-02-07
RU2019106483A (ru) 2020-09-11
US20190167649A1 (en) 2019-06-06
CN109689053A (zh) 2019-04-26
KR20190039220A (ko) 2019-04-10
MX2019001670A (es) 2019-07-04
RU2019106483A3 (enExample) 2020-12-04
JP2019527711A (ja) 2019-10-03
EP3496712A1 (en) 2019-06-19

Similar Documents

Publication Publication Date Title
US20190167649A1 (en) Topical rapamycin therapy
US12268673B2 (en) Anhydrous compositions of mTOR inhibitors and methods of use
JP6438466B2 (ja) イベルメクチンによる丘疹膿疱性の酒さの治療
ES2627405T3 (es) Composiciones que comprenden brimonidina para el tratamiento del eritema
US20120321579A1 (en) Surfactant compositions
US20130102572A1 (en) Methods of treating skin conditions exhibiting telangiectasia
US20250114497A1 (en) Skin composition
JP2019507758A (ja) プリドピジンを使用する神経変性眼疾患の治療
JP2021530463A (ja) ｍＴＯＲ阻害剤の無水組成物および使用方法
IL269182B2 (en) Methods for the treatment and/or prevention of actinic radiation
JP2006522059A (ja) 皮膚疾患の処置にて使用するための免疫抑制剤を含んでなる医薬組成物
Stein et al. Betamethasone valerate foam for treatment of nonscalp psoriasis
ES2351045T3 (es) Utilización de una composición farmacéutica que comprende calcitriol y propionato de clobetazol para el tratamiento de la psoriasis.
JP2024507266A (ja) ヒドロゲル組成物、ならびに放射線によって引き起こされる皮膚損傷の予防および／または処置におけるその使用
TWI863995B (zh) 皮膚型紅斑狼瘡之治療
JP2017502053A (ja) 炎症性皮膚状態を治療するためのアラントイン組成物
JP6929860B2 (ja) 手湿疹の治療
US7357938B2 (en) Sulfacetamide formulations for treatment of rosacea
US10772813B2 (en) Compositions and methods of administering a colchicine based topical composition for the prevention of radiation fibrosis
EP4114357B1 (en) Topical formulations containing mtor inhibitors
WO2023039470A1 (en) Anhydrous compositions of egfr inhibitors and methods of use
JP5513705B2 (ja) 知覚過敏型肌掻痒感改善剤
JP2007262030A (ja) 皮膚外用剤
US8501202B2 (en) Sulfacetamide formulations for treatment of skin dermatoses
Sigg et al. A survey of patients with facial angiofibromas associated with tuberous sclerosis complex: Short-, medium-and long-term efficacy and safety of topical rapamycin

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20231107